Valproic Acid
Coma
University of North Carolina, Chapel HillSmall moleculePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Coma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dipeptiven University of Zurich | Phase 4 | BB |
Keppra University of North Carolina, Chapel Hill | Phase 4 | BB |
Lacosamide University of North Carolina, Chapel Hill | Phase 4 | BB |
Fosphenytoin University of North Carolina, Chapel Hill | Phase 4 | B |
Baclofen University Hospital, Bordeaux | Phase 2 | CCC |
Phenobarbital University of North Carolina, Chapel Hill | Phase 4 | CCC |
Methylphenidate Massachusetts General Hospital | Phase 1 | CC |
Amantadine Hamilton Health Sciences Corporation | N/A | D |
Same molecule, other indications
Valproic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →